3:57 AM
 | 
May 07, 2019
 |  BioCentury  |  Finance

Confo’s €30M growth plan

BioGeneration, Wellington lead series A for GPCR agonist company Confo

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round, announced on Tuesday and co-led by the firms, will help the Belgian company push its lead fibrosis candidate into Phase I testing and develop at least two more compounds for orphan diseases.

Since Confo Therapeutics N.V. spun out of Flanders Institute for Biotechnology (VIB)...

Read the full 374 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >